The minority report: targeting the rare oncogenes in NSCLC.

ABSTRACT:

Opinion statement

Lung cancer is still responsible for the highest number of cancer deaths worldwide. Despite this fact, significant progress has been made in the treatment of non-small cell lung cancer (NSCLC). Specifically, efforts to identify and treat genetic alterations (gene mutations, gene fusions, gene amplification events, etc.) that result in oncogenic drivers are now standard of care (EGFR and ALK) or an intense area of research. The most prevalent oncogenic drivers have likely already been identified; thus, there is now a focus on subgroups of tumors with less common genetic alterations. Interestingly, as we explore these less common mutations, we are discovering that many occur across other tumor types (i.e., non-lung cancer), further justifying their study. Furthermor

SUBMITTER: McCoach CE 

PROVIDER: S-EPMC4216615 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature